Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3217 in advanced solid tumors
NCT07291050Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3217 in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
TQB3217
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07291050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07291050.